Pfizer sues Johnson & Johnson for alleged monopolistic behaviour

In a move the company is touting as an attempt to get lower-cost biosimilar medicines into the hands of patients, Pfizer has sued Johnson & Johnson for alleged anticompetitive behaviour in the growing biologics market.

Unlock unlimited access to all Global Competition Review content